Daiichi Sankyo Co Ltd on Monday said it dosed the first patient in the Tropion-Breast02 phase three trial, evaluating the safety and efficacy of datopotamab deruxtecan in patients with breast cancer.

The trial evaluated patients with previously untreated locally recurrent inoperable or metastatic triple negative breast cancer who are eligible to receive PD-1/PD-L1 inhibitor therapy.

The treatment is being jointly developed by Daiichi Sankyo and AstraZeneca PLC.

‘Initial results of datopotamab deruxtecan in patients with pretreated metastatic triple negative breast cancer, a group with a significant unmet need, have been encouraging. We are building on these early results by moving forward with the Tropion-Breast02 trial, the second pivotal trial of datopotamab deruxtecan in breast cancer, to determine if this antibody drug conjugate may potentially be used earlier in the treatment of metastatic triple negative breast cancer,’ said Cristian Massacesi, chief medical officer at AstraZeneca.

Shares in Daiichi Sankyo closed down 1.9% at JP¥3,305.00 on Monday in Tokyo, while shares in AstraZeneca were down 0.5% at 9,801.00 pence in London.

Copyright 2022 Alliance News Limited. All Rights Reserved.